We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
Read MoreHide Full Article
Key Takeaways
Hims & Hers is deepening its care platform by linking diagnostics, providers, and pharmacy fulfillment.
HIMS' new offerings include Labs for biomarker testing and menopause care guided by hormonal health experts.
At-home testosterone services show HIMS unifying testing, treatment and provider oversight in men's health.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates as a connected healthcare platform rather than a single-product provider, consistently linking consumers with licensed clinicians, diagnostics and pharmaceutical partners. The company’s model is built around provider-guided evaluations, personalized treatment plans and integrated pharmacy fulfillment — an ecosystem designed to coordinate care rather than deliver isolated transactions. This structure enables patients to move seamlessly from intake to diagnosis to long-term management within one environment.
Recent launches strengthen this role. The new Labs offering brings whole-body diagnostic testing into the platform, giving customers biomarker insights accompanied by clinician-developed action plans and access to tailored treatments when appropriate. The menopause and perimenopause specialty similarly connects women to providers trained in hormonal health, expanding treatment options while ensuring ongoing clinical oversight. In men’s health, the introduction of innovative testosterone treatments — supported by at-home testing and provider review — illustrates how Hims & Hers integrates pharmaceutical collaboration, diagnostics and personalized care into a unified pathway.
Together, these developments show HIMS expanding the number of touchpoints it coordinates across the healthcare ecosystem. Each launch increases the flow of information between diagnostics, clinicians and patients, making the platform a comprehensive connector that supports proactive, personalized care at scale — rather than a seller of discrete products.
GoodRx Holdings, Inc. (GDRX - Free Report) sits at the center of the prescription ecosystem, connecting consumers, prescribers, pharmacies, pharmacy benefit managers and drug manufacturers rather than just issuing discount codes. GoodRx for Weight Loss links telemedicine visits with licensed providers, GLP-1 prescriptions and nationwide in-store pickup or home delivery at negotiated cash prices. GoodRx for Hair Loss combines virtual consults, clinically proven medications and discreet shipping in one subscription. GDRX also powers RxSmartSaver at Kroger, tying manufacturers’ affordability programs directly to pharmacy counters and patients.
Doximity, Inc. (DOCS - Free Report) is built as a platform where doctors, health systems, and life-science companies connect and work together, not just as a basic advertising tool. Doximity connects its verified clinician base to pharmaceutical and health-system customers through targeted Marketing and Hiring Solutions, while its workflow tools — telehealth, scheduling, digital fax and AI Scribe — link doctors and patients inside everyday care. With the Pathway acquisition integrated into DoxGPT, Doximity now fuses AI clinical reference with its newsfeed and workflows so Doximity members can bring evidence and documentation directly to the point of care.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 39.1% year to date, outperforming the industry’s growth of 9.4%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.8X is lower than the industry’s average of 5.1X, but is higher than its three-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates as a connected healthcare platform rather than a single-product provider, consistently linking consumers with licensed clinicians, diagnostics and pharmaceutical partners. The company’s model is built around provider-guided evaluations, personalized treatment plans and integrated pharmacy fulfillment — an ecosystem designed to coordinate care rather than deliver isolated transactions. This structure enables patients to move seamlessly from intake to diagnosis to long-term management within one environment.
Recent launches strengthen this role. The new Labs offering brings whole-body diagnostic testing into the platform, giving customers biomarker insights accompanied by clinician-developed action plans and access to tailored treatments when appropriate. The menopause and perimenopause specialty similarly connects women to providers trained in hormonal health, expanding treatment options while ensuring ongoing clinical oversight. In men’s health, the introduction of innovative testosterone treatments — supported by at-home testing and provider review — illustrates how Hims & Hers integrates pharmaceutical collaboration, diagnostics and personalized care into a unified pathway.
Together, these developments show HIMS expanding the number of touchpoints it coordinates across the healthcare ecosystem. Each launch increases the flow of information between diagnostics, clinicians and patients, making the platform a comprehensive connector that supports proactive, personalized care at scale — rather than a seller of discrete products.
GDRX & DOCS’ Integrated Healthcare Connectivity Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) sits at the center of the prescription ecosystem, connecting consumers, prescribers, pharmacies, pharmacy benefit managers and drug manufacturers rather than just issuing discount codes. GoodRx for Weight Loss links telemedicine visits with licensed providers, GLP-1 prescriptions and nationwide in-store pickup or home delivery at negotiated cash prices. GoodRx for Hair Loss combines virtual consults, clinically proven medications and discreet shipping in one subscription. GDRX also powers RxSmartSaver at Kroger, tying manufacturers’ affordability programs directly to pharmacy counters and patients.
Doximity, Inc. (DOCS - Free Report) is built as a platform where doctors, health systems, and life-science companies connect and work together, not just as a basic advertising tool. Doximity connects its verified clinician base to pharmaceutical and health-system customers through targeted Marketing and Hiring Solutions, while its workflow tools — telehealth, scheduling, digital fax and AI Scribe — link doctors and patients inside everyday care. With the Pathway acquisition integrated into DoxGPT, Doximity now fuses AI clinical reference with its newsfeed and workflows so Doximity members can bring evidence and documentation directly to the point of care.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 39.1% year to date, outperforming the industry’s growth of 9.4%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.8X is lower than the industry’s average of 5.1X, but is higher than its three-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.